文献速递腹部介入CTMR

晚期肝细胞癌AB失败后二线HAIC对比TKI的疗效

Comparison of Second-line Hepatic Arterial Infusion Chemotherapy and Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma.
PubMed 文献 · Radiology · 2026-01-01

多中心回顾性研究纳入90例接受阿替利珠单抗-贝伐珠单抗(AB)失败后的晚期肝细胞癌患者,比较二线肝动脉灌注化疗(HAIC)与酪氨酸激酶抑制剂(TKI)的结局。HAIC组客观缓解率、疾病控制率及无进展生存期均优于TKI组,总生存期两组相似。经逆概率加权后HAIC仍保持无进展生存优势。

要点

  • AB失败后二线HAIC的客观缓解率和无进展生存期优于TKI,总生存期无显著差异。
  • HAIC组基线肿瘤负荷更高,超出up-to-seven标准的比例显著高于TKI组。
  • 影像评估采用多期增强CT或肝脏MRI,由对治疗分组设盲的放射科医师审阅。

核心结论

  • 晚期肝细胞癌患者在AB失败后,二线HAIC较TKI获得更高缓解率和更长无进展生存期。
  • 总生存期在HAIC组与TKI组之间无显著差异,加权前后结论一致。

研究设计与样本

  • 多中心回顾性研究,纳入2022年3月至2025年8月期间接受AB后序贯HAIC或TKI的90例晚期肝细胞癌患者。
  • HAIC组51例,采用顺铂-氟尿嘧啶方案;TKI组39例,给予标准剂量。
  • 影像评估方法为多期增强CT或肝脏MRI,按常规临床实践进行,由对治疗分组设盲的放射科医师审阅。
  • 采用逆概率治疗加权校正年龄、性别、ECOG体能状态、Child-Pugh分级、门静脉癌栓及基于up-to-seven标准的肿瘤负荷。

关键影像表现/征象

  • 影像学肿瘤反应评估依据多期增强CT或肝脏MRI,按常规临床实践判定客观缓解和疾病控制。
  • HAIC组基线肿瘤负荷更高,超出up-to-seven标准的患者比例为88%(45/51),TKI组为64%(25/39)。

诊断标准与关键数值

  • 未加权分析中,HAIC组客观缓解率为35%(18/51),TKI组为5%(2/39),P = .002。
  • 未加权分析中,HAIC组疾病控制率为67%(34/51),TKI组为26%(10/39),P < .001。
  • 未加权分析中,HAIC组中位无进展生存期为5.3个月,TKI组为3.6个月,P = .008。
  • 逆概率加权后,HAIC组中位无进展生存期为7.1个月,TKI组为3.4个月,P < .001。
  • 未加权分析中,HAIC组中位总生存期为10.4个月,TKI组为6.4个月,P = .62;加权后分别为10.5个月与6.3个月,P = .32。

临床应用与阅片要点

  • 影像随访中应重点关注有无符合客观缓解的病灶缩小或坏死,以区分HAIC与TKI的疗效差异。
  • 基线肿瘤负荷评估对解读两组疗效差异有参考价值,HAIC组肿瘤负荷更高但缓解率仍更优。
  • 报告时应注明采用多期增强CT或肝脏MRI并按常规临床实践标准判定肿瘤反应。

局限性

  • 回顾性研究设计存在选择偏倚可能,尽管采用逆概率治疗加权进行校正。
  • 两组基线肿瘤负荷不均衡,HAIC组肿瘤负荷显著更高。
  • 影像评估按常规临床实践进行,未提及统一或标准化的疗效评价标准如RECIST或mRECIST。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background With the advent of immune checkpoint inhibitor-based combination therapy, treatment sequencing for advanced hepatocellular carcinoma (HCC) has become increasingly complex. The Barcelona Clinic Liver Cancer (BCLC) 2026 recommendations emphasize individualized decision-making. Purpose To compare clinical outcomes of hepatic arterial infusion chemotherapy (HAIC) and tyrosine kinase inhibitors (TKIs) in patients with advanced HCC after atezolizumab-bevacizumab (AB) failure, within the BCLC 2026 treatment paradigm. Materials and Methods This multicenter retrospective study included patients who received AB and subsequently received either HAIC or a TKI between March 2022 and August 2025. HAIC used a cisplatin-fluorouracil regimen, and TKIs were given at standard doses. Tumor response and progression-free survival (PFS) were assessed using contrast-enhanced multiphase CT or liver MRI according to routine clinical practice. Imaging was reviewed by radiologists blinded to treatment allocation. Inverse probability of treatment weighting (IPTW) was applied for age, sex, Eastern Cooperative Oncology Group performance status, Child-Pugh class, portal vein tumor thrombosis, and tumor burden based on the up-to-seven criteria. Results This study included 90 patients (mean age, 62 years ± 10.9 [SD]; 73 men; HAIC group, n = 51; TKI group, n = 39). Baseline tumor burden was higher in the HAIC group than in the TKI group (percentage of patients with tumors beyond the up-to-seven criteria: 88% [45 of 51] vs 64% [25 of 39]; P = .01). In unweighted analyses, median overall survival (OS) was similar between the HAIC and TKI groups (10.4 vs 6.4 months; P = .62), whereas PFS favored HAIC over TKIs (median, 5.3 vs 3.6 months; P = .008). Objective response rate and disease control rate were higher with HAIC than with TKIs (objective response rate: 35% [18 of 51] vs 5% [two of 39], P = .002; disease control rate: 67% [34 of 51] vs 26% [10 of 39], P < .001). After IPTW, HAIC remained associated with longer PFS than TKIs (median, 7.1 vs 3.4 months; P < .001), and OS remained similar between groups (median, 10.5 vs 6.3 months; P = .32). Conclusion In patients with advanced HCC, after AB failure, second-line HAIC yielded higher response rates and longer PFS than TKIs. © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Deyirmendjian and Tang in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Yoo, Tak, Cho, et al. Comparison of Second-line Hepatic Arterial Infusion Chemotherapy and Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma. Radiology. 2026. PMID: 42550027. doi:10.1148/radiol.253280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。